Glucagon, GIP, and GLP-1: How These Three Hormones Control Weight, Blood Sugar, and Appetite

What GLP-1 Is and Where It Comes From

GLP-1 (glucagon-like peptide-1) is a 30-amino-acid peptide secreted by intestinal L-cells within minutes of a meal. It acts on pancreatic beta cells, the hypothalamus, the brainstem, and the vagus nerve simultaneously. Native GLP-1 is destroyed by the enzyme DPP-4 with a plasma half-life of roughly 90 seconds, which is why pharmacologic analogs engineered to resist DPP-4 cleavage are required for therapeutic use [1].

The two biologically active forms are GLP-1(7-36) amide and GLP-1(7-37). Both bind the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor. Receptor activation raises intracellular cAMP, which potentiates glucose-stimulated insulin secretion. Because the response is glucose-dependent, GLP-1R stimulation carries a low intrinsic hypoglycemia risk when used without sulfonylureas or insulin [2].

L-cells also co-secrete peptide YY (PYY), another satiety signal, meaning a single meal triggers parallel anorexigenic hormones from the same cell population [3]. The total postprandial GLP-1 area under the curve is blunted in individuals with obesity, a deficit that pharmacologic GLP-1R agonism directly compensates for [4].

Semaglutide, the active ingredient in Ozempic (0.5 to 2 mg weekly, type 2 diabetes) and Wegovy (2.4 mg weekly, obesity), shares 94% amino-acid homology with native GLP-1 but has a C-18 fatty-acid chain that binds albumin and extends its half-life to approximately 165 to 184 hours [5]. The FDA-approved Wegovy label specifies a maintenance dose of 2.4 mg subcutaneously once weekly [6].

What GIP Is and Why It Matters More Than Once Thought

GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin. It is secreted by duodenal and jejunal K-cells within minutes of fat and carbohydrate ingestion and historically contributed roughly 50% of the total incretin effect on insulin release [7].

For decades, GIP was considered a poor drug target because GIP receptor agonism alone does not significantly reduce body weight in humans with obesity, and early data suggested GIP might even promote fat storage. Tirzepatide upended that assumption. It is a 39-amino-acid synthetic peptide that acts as a dual GIP/GLP-1 receptor agonist, exploiting GIP's ability to sensitize adipocytes to insulin and to synergize with GLP-1 signaling in the hypothalamus [8].

GIP receptors are expressed in adipose tissue, bone, and the central nervous system, not just the pancreas. Activation in adipose tissue during a caloric deficit appears to redirect free fatty acids toward oxidation rather than storage, a mechanism distinct from anything GLP-1 alone provides [9]. This tissue-distribution difference likely explains why combining GIP and GLP-1 receptor activation produces additive metabolic effects.

In SURMOUNT-1 (N=2,539, tirzepatide vs. placebo in adults with obesity), the 15 mg dose produced a mean 20.9% reduction in body weight at 72 weeks versus 3.1% for placebo (P<0.001), with 56.8% of participants reaching at least 20% weight loss [10]. That figure substantially exceeds the 14.9% mean weight loss seen with semaglutide 2.4 mg in STEP-1 (N=1,961 to 68 weeks, P<0.001) [11].

What Glucagon Does and How It Fits Into the Axis

Glucagon is a 29-amino-acid peptide from pancreatic alpha cells. Its canonical role is to raise blood glucose during fasting by stimulating hepatic glycogenolysis and gluconeogenesis. In people with type 2 diabetes, postprandial glucagon suppression fails, contributing directly to postprandial hyperglycemia [12].

GLP-1 receptor agonism suppresses pathologically elevated glucagon secretion, which accounts for roughly 30 to 40% of the HbA1c reduction seen with semaglutide in clinical trials [13]. GIP receptor agonism also inhibits glucagon, but primarily in a hyperglycemic context; at euglycemia and in hypoglycemia, GIP receptor stimulation can paradoxically raise glucagon, which may reduce hypoglycemia risk [14].

Glucagon coagonism is the next frontier. Triple agonist compounds combining GLP-1R, GIPR, and glucagon receptor (GCGR) activity are in phase 2 and phase 3 trials. GCGR stimulation increases hepatic fatty acid oxidation, raises resting energy expenditure, and shows early efficacy in reducing liver fat in non-alcoholic fatty liver disease models [15]. Retatrutide, a GLP-1/GIP/glucagon triple agonist, produced 24.2% mean weight loss at 48 weeks in a phase 2 trial (N=338), the largest figure published for any pharmacologic agent in that duration [16].

How GLP-1 Slows Gastric Emptying

Delayed gastric emptying is one of GLP-1's most clinically significant peripheral actions. GLP-1 receptors on vagal afferent neurons and on gastric smooth muscle slow the rate at which chyme moves from the stomach into the duodenum, reducing the speed of glucose absorption and blunting postprandial glucose excursions [17].

In controlled scintigraphy studies, pharmacologic GLP-1R agonism slows solid-food gastric emptying by approximately 20 to 30% compared with baseline [18]. This effect is dose-dependent and most pronounced in the first hour after a meal, precisely when postprandial glucose peaks.

The clinical implication is bidirectional. Slower emptying helps glycemic control and prolongs mechanical satiety. It also raises the concern of gastroparesis-like symptoms at higher doses, which is why all approved GLP-1R agonist labels include a dose-escalation schedule and a precaution for patients with pre-existing gastroparesis [6]. The Wegovy label notes nausea rates of 44% and vomiting rates of 24% at the 2.4 mg maintenance dose, most episodes occurring during the up-titration phase [6].

Gastric emptying rate also interacts with oral drug absorption. Patients on levothyroxine, warfarin, or oral contraceptives who start GLP-1R agonist therapy should have therapeutic monitoring reviewed, because slower transit changes time-to-peak absorption for narrow-therapeutic-index drugs [19].

How GLP-1 and GIP Signal Satiety in the Brain

Satiety signaling is where GLP-1 arguably has its most durable clinical impact. GLP-1 receptors are expressed in the arcuate nucleus, paraventricular nucleus, nucleus tractus solitarius (NTS), and area postrema of the hypothalamus and brainstem. Activation of these receptors reduces food intake by increasing the firing of pro-opiomelanocortin (POMC) neurons and reducing neuropeptide Y (NPY)/AgRP neuron activity [20].

Central GLP-1R activation also modifies reward-related eating behavior. Neuroimaging studies show that GLP-1R agonists reduce activity in the caudate nucleus and putamen in response to images of high-calorie foods, consistent with reduced food reward salience [21]. Patients on semaglutide commonly report lower cravings for fatty and sweet foods independent of caloric restriction instructions, a behavioral phenotype that aligns with these central receptor data.

GIP receptors in the hypothalamus appear to amplify this anorexigenic signal when co-stimulated. Rodent studies with GIPR-knockout animals show that the weight-loss effect of dual GIP/GLP-1 agonists is partially lost, confirming the central GIPR's independent contribution [22]. The human correlate is visible in clinical outcomes: tirzepatide 15 mg produced mean weight loss of 20.9% in SURMOUNT-1 [10], whereas the best GLP-1-only outcome in a head-to-head semaglutide trial remains approximately 15 to 16%.

Vagal afferent neurons carry the peripheral satiety signal to the NTS within seconds of gastric stretch and GLP-1 binding. That fast vagal arc complements the slower hormonal arc through the bloodstream, layering two different time-constant signals to sustain fullness well past the immediate postprandial window [23].

Clinical Outcomes: What the Trials Show

The STEP program (semaglutide 2.4 mg, Novo Nordisk) and the SURMOUNT program (tirzepatide, Eli Lilly) provide the highest-quality evidence on what activating these receptor axes achieves in clinical practice.

STEP-1 (N=1,961 to 68 weeks) showed 14.9% mean body-weight loss with semaglutide 2.4 mg vs. 2.4% with placebo; 69.1% of treated participants achieved at least 10% weight loss [11]. STEP-3 added intensive behavioral therapy to semaglutide 2.4 mg and produced 16.0% mean weight loss at 68 weeks (N=611) compared with 5.7% for placebo plus behavioral therapy [24]. STEP-5 extended observation to 104 weeks and found sustained 15.2% mean weight loss with semaglutide, with no apparent plateau signal at two years [25].

STEP-2 (N=1,210, adults with type 2 diabetes, 68 weeks) demonstrated 9.6% weight loss with semaglutide 2.4 mg vs. 3.4% placebo, alongside a 1.6 percentage-point reduction in HbA1c [26]. Glycemic outcomes in the presence of obesity-related insulin resistance confirm that the GLP-1/GIP axis is not a single-disease mechanism but a multi-system metabolic regulator.

SURMOUNT-2 (N=938, tirzepatide in type 2 diabetes, 72 weeks) showed 15.7% weight loss with tirzepatide 15 mg vs. 3.3% placebo, and HbA1c fell by 2.1 percentage points [27]. SURMOUNT-4 (N=670, tirzepatide vs. placebo after 36 weeks of open-label tirzepatide) found that discontinuation reversed 14.8% of weight loss at 88 weeks post-randomization, illustrating that ongoing receptor stimulation is required to maintain the anorexigenic state [28].

The SELECT trial (N=17,604, semaglutide 2.4 mg, adults with obesity and established cardiovascular disease but no diabetes) showed a 20% relative risk reduction in major adverse cardiovascular events (MACE) at a median 34.2 months, with a hazard ratio of 0.80 (95% CI 0.72, 0.90, P<0.001) [29]. That cardiovascular outcome is independent of weight loss magnitude, suggesting direct GLP-1R signaling in cardiac and vascular tissue contributes to the benefit.

For a direct comparison within the GLP-1R agonist class, STEP-8 (N=338 to 68 weeks) placed semaglutide 2.4 mg head-to-head against liraglutide 3.0 mg and showed 15.8% vs. 6.4% mean weight loss respectively (P<0.001), establishing semaglutide as the more effective GLP-1-only agent currently approved for obesity [30].

Tirzepatide vs. Semaglutide: Choosing Between Single and Dual Receptor Activation

Both drugs share nausea, vomiting, and constipation as their dominant adverse effects due to GLP-1R-mediated gastric slowing. The profiles diverge in several specific areas.

Tirzepatide's GIPR activity adds a pancreatic glucagon-sparing effect in hypoglycemia, which may make it preferable in patients at hypoglycemia risk on combination regimens. Its adipose-tissue GIPR activity appears to reduce visceral fat preferentially: in SURMOUNT-1, tirzepatide 15 mg reduced waist circumference by a mean 14.5 cm, and DEXA sub-studies confirmed preferential visceral adipose tissue reduction [10].

Semaglutide has the longer cardiovascular outcomes database. SELECT published MACE data in 2023 [29]; the equivalent tirzepatide cardiovascular outcomes trial (SURPASS-CVOT) is ongoing as of early 2025. Clinicians who need established MACE data today should note semaglutide's current edge in that specific evidence category.

AACE/ACE obesity guidelines state that "pharmacotherapy should be considered for all patients with BMI >30 kg/m2 or BMI >27 kg/m2 with at least one weight-related comorbidity who have not achieved adequate weight loss with lifestyle intervention alone" [31]. Both agents fit within that framework; drug selection depends on insurance coverage, cardiovascular history, and glycemic status.

The HealthRX clinical team uses a three-factor triage at first consult: (1) HbA1c at screening, since tirzepatide's dual mechanism provides a larger HbA1c reduction and may reduce the need for add-on antihyperglycemics; (2) prior GI intolerance, since both drugs require 16 to 20 weeks of dose titration but individual tolerance varies; and (3) payer formulary, since tirzepatide carries a list price roughly 10 to 15% higher than semaglutide 2.4 mg for obesity indications.

GLP-1 Receptor Agonist Dose Titration and Gastric Emptying Tolerance

Dose escalation is not optional. It is the mechanism by which GI adverse events are minimized while receptor occupancy builds. The approved Wegovy schedule begins at 0.25 mg weekly for four weeks, advances every four weeks, and reaches the 2.4 mg maintenance dose at week 17 [6]. The Zepbound (tirzepatide) schedule begins at 2.5 mg weekly and reaches the maximum 15 mg dose at week 20, with 2.5 mg increments every four weeks [32].

Gastric emptying slowing is present even at subtherapeutic doses. Patients who begin the titration and consume high-fat, high-volume meals in the first four weeks report the highest nausea rates, not because the drug dose is maximal but because gastric accommodation reflexes are blunted by even low-level GLP-1R activation [18]. Prescribing clinicians should advise smaller, lower-fat meals during the first two titration steps as a practical mitigation strategy backed by the tolerability data in both FDA labels.

Non-Alcoholic Fatty Liver Disease and the Glucagon Axis

Non-alcoholic fatty liver disease (NAFLD) affects an estimated 25% of adults globally, and NASH (non-alcoholic steatohepatitis) is increasingly the primary indication driving investigation of glucagon receptor coagonism [33]. GLP-1R agonism reduces hepatic fat by decreasing hepatic lipogenesis and improving insulin sensitivity, but glucagon receptor agonism adds direct hepatic fat oxidation that GLP-1 alone does not provide.

Semaglutide reduced liver fat content by a mean 40% relative to baseline in a 72-week NASH trial (N=320), with 59% of treated patients showing NASH resolution on biopsy vs. 17% placebo, though fibrosis regression did not reach statistical significance [34]. Retatrutide's phase 2 results in subjects with metabolic dysfunction-associated steatotic liver disease showed MRI-PDFF hepatic fat reduction of 81.4% at 24 weeks in the highest-dose group [16], a signal that the glucagon receptor adds meaningful hepatic benefit beyond what dual GIP/GLP-1 agonism delivers.

Peptide Biology: Why Native GLP-1 Cannot Be Given as a Drug

The 90-second plasma half-life of native GLP-1 [1] is not a limitation to work around; it is the physiologic design. Rapid DPP-4 cleavage prevents tonic receptor activation, which would blunt receptor sensitivity. Pharmacologic GLP-1R agonists survive DPP-4 by various structural strategies: semaglutide uses Aib8 substitution plus C-18 fatty-acid albumin binding [5]; liraglutide uses a C-16 fatty acid; exenatide uses a proline at position 8; tirzepatide uses a novel non-native amino-acid sequence with a C20 fatty-diacid chain [8].

Each structural modification shifts the receptor binding kinetics. Semaglutide is a full GLP-1R agonist with high receptor occupancy at 165-hour half-life doses; tirzepatide is a biased agonist at the GLP-1R with relatively lower GLP-1R potency than semaglutide but adds complete GIPR agonism [8]. The clinical consequence is that tirzepatide's GLP-1R component alone does not explain its efficacy, which is why naive comparisons to liraglutide or exenatide underestimate the mechanism.

DPP-4 inhibitors (sitagliptin, saxagliptin) take the opposite pharmacologic approach: rather than providing a stable GLP-1 analog, they block the enzyme that degrades native GLP-1, raising its plasma concentration two-to-threefold. The result is a modest HbA1c reduction of approximately 0.6, 0.8 percentage points and minimal weight loss, confirming that the concentration of native GLP-1 achieved by DPP-4 inhibition is insufficient to match receptor-agonist pharmacology [35].

Insulin Secretion: Glucose-Dependence as a Safety Feature

The glucose-dependence of GLP-1R-mediated and GIPR-mediated insulin secretion is the mechanistic reason these drugs carry low hypoglycemia risk as monotherapy. Both GLP-1R and GIPR are coupled to adenylyl cyclase via Gs proteins; cAMP production amplifies K-ATP channel closure and calcium influx in beta cells, but only when intracellular glucose metabolism is sufficient to provide the primary signal. Below approximately 70 mg/dL (3.9 mmol/L), this amplification mechanism loses its substrate-dependent trigger [2].

The practical consequence: in STEP-1, hypoglycemia rates with semaglutide 2.4 mg were 0.4% for confirmed episodes below 54 mg/dL, not significantly different from placebo [11]. In SURMOUNT-1, symptomatic hypoglycemia occurred in 0.2% of tirzepatide-treated participants without background insulin or sulfonylurea [10]. Hypoglycemia risk rises substantially when either agent is combined with insulin or a sulfonylurea, warranting pre-emptive dose reduction of those agents at GLP-1R agonist initiation per both FDA labels [6, 32].